Elacestrant Bests Standard of Care in PFS in ER Positive/HER2-Negative Metastatic Breast Cancer
Patients with ER-positive/HER2-negative metastatic breast cancer had improved progression-free survival when treated with elacestrant compared with standard of endocrine therapy.
Trastuzumab Deruxtecan Improves Survival in HER-2 Positive Breast Cancer Compared to Capecitabine Regimens
Patients with advanced HER2-positive breast cancer had improved progression-free and overall survival when treated with trastuzumab deruxtecan compared with capecitabin-based treatment, according to recent findings.